Event rates for thrombosis were comparable between pegcetacoplan and previously reported rates of C5 inhibitors in patients with PNH, and no cases of meningococcal infection were reported with pegcetacoplan. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.